

08/25/00  
jc803 U.S. PTO

BERESKIN & PARR

BOX 401, 40 KING STREET WEST, TORONTO, CANADA M5H 3Y2  
PHONE (416) 364-7311 • FAX (416) 361-1398 • WWW.BERESKINPARR.COM

jc864 U.S. PTO  
09/645594  
08/25/00

Please type a plus sign (+) inside this box → ☒

Approved for use through 09/30/2000. OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY  
PATENT APPLICATION  
TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No.	11157-14
First Inventor or Application Identifier	Malcolm King
Title	Use of Charged Dextran As A Mucoactive Agent and ...
Express Mail Label No.	

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

- ☒ \* Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)
- ☒ Specification [Total Pages 34]  
(preferred arrangement set forth below)
  - Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to Micro fiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
- ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 5]
- Oath or Declaration [Total Pages ]
  - ☐ Newly executed (original or copy)
  - ☐ Copy from a prior application (37 C.F.R. § 1.63(d))  
(for continuation/divisional with Box 16 completed)
    - ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

- ☐ Microfiche Computer Program (Appendix)
- ☐ Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
  - ☐ Computer Readable Copy
  - ☐ Paper Copy (identical to computer copy)
  - ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- ☐ Assignment Papers (cover sheet & document(s))
- ☐ 37 C.F.R. § 3.73(b) Statement of Power of Attorney  
(when there is an assignee)
- ☐ English Translation Document (if applicable)
- ☐ Information Disclosure Statement (IDS)/PTO-1449 [Copies of IDS Citations]
- ☐ Preliminary Amendment
- ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
- ☐ \* Small Entity Statement filed in prior application, Status still proper and desired  
(PTO/SB/09-12)
- ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
- ☒ Other: Unsigned Declaration

\* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:

Prior application information: Examiner: Group / Art Unit:

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label 1059 or ☐ Correspondence address below  
(Insert Customer No. or Attach bar code label here)

Name	Bereskin & Parr				
Address	Box 401 40 King Street West				
City	Toronto	State	Ontario	Zip Code	M5H 3Y2
Country	Canada	Telephone	(416) 364-7311	Fax	(416) 361-1398

Name (Print/Type)	Micheline Gravelle	Registration No. (Attorney/Agent)	40.261
Signature	<i>M. Gravelle</i>	Date	August 24, 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Office, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Our File No: 11157-14

**BERESKIN & PARR**  
Box 401  
40 King Street West  
Toronto, Canada  
M5H 3Y2

Telephone (416) 364-7311  
Telecopies (416) 361-1398  
Internet BERESKIN&PARR.COM  
Cable ARNBEE Toronto

August 24, 2000

The Commissioner of Patents & Trademarks  
Washington, D.C., U.S.A. 20231

Dear Sir:

Transmitted herewith for filing is the patent application of

Inventors: **Malcolm King**

For: **Use of Charged Dextran as a Mucoactive Agent and Methods and Pharmaceutical Compositions Relating Thereto**

The following papers are also enclosed:

[X] 5 sheets of X Formal drawings \_\_\_\_\_ Informal drawings

[X] A Declaration (Unsigned)

	Number Extra	Full Rate	Small Entity Rate	Total
Total Claims	28 - 20 = 8 X	\$ 18.00	\$ 9.00	\$72.00
Independent Claims	3 - 3 = 0 X	\$ 78.00	\$ 39.00	\$0.00
Multiple Claims	Flat Rate	\$260.00	\$130.00	\$0.00

Basic Fee = \$345.00  
TOTAL FEES = \$417.00

- [X] Please charge Deposit Account No. 02-2095 in the amount of \$ 417.00. This letter is enclosed in duplicate.
- [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Account No. 02-2095. This letter is enclosed in duplicate.
- [ ] Payment Of The Filing Fee Is Being Deferred.
- [ ] Related application. This application is a \_\_\_\_\_ Division \_\_\_\_\_ Continuation \_\_\_\_\_ Continuation-in-part of application Serial No. \_\_\_\_\_, filed \_\_\_\_\_.
- [X] Convention priority is requested based on U.S. Provisional Application Serial No. 60/150,605 filed August 26, 2000 under 35 USC §119(e).

Respectfully submitted,

*M. Gravelle*

Micheline Gravelle  
Registration No. 40,261



BERESKIN & PARR

UNITED STATES

Title: USE OF CHARGED DEXTRAN AS A MUCOACTIVE AGENT AND  
METHODS AND PHARMACEUTICAL COMPOSITIONS  
RELATING THERETO

Inventors: Malcolm King

005262 1654560

Mucokinetic therapy combating mucus retention is a major consideration in the treatment of cystic fibrosis (CF), and other chronic lung diseases in which mucus hypersecretion and impaired airway clearance produce symptoms.

5 Mucus is a nonhomogeneous, adhesive, viscoelastic gel consisting of water and high molecular weight, crosslinked glycoproteins mixed with serum and cellular proteins (albumin, enzymes, and immunoglobulins), ions and lipids.

10 The physical, three-dimensional structure that forms the mucous gel is dependent upon a number of forms of bonding: 1) intramolecular disulfide bonds [3, 4]; 2) entanglements with neighboring macromolecules [5]; 3) hydrogen bonds between oligosaccharide side-chains [6]. Although each bond is weak, the number of bond sites make hydrogen-bonding a potentially important target for mucolytic  
15 therapy; 4) ionic interactions between fixed negative charges [7, 8]; 5) extra networks of high molecular weight DNA and actin filaments released by dying leukocytes [8 - 10]. Each of these elements is a potential target for mucoactive therapy.

20 One of the primary aspects of the current treatment of lung diseases associated with impaired mucus clearance, such as CF, is aimed at changing the physical properties of the mucous gel. For instance, intramolecular disulfide bonds in mucus are the target of classic mucolytic agents such as N-acetylcysteine [3, 4]. Entanglements with neighbouring macromolecules are susceptible to mechanical degradation and can be  
25 reduced by high frequency oscillation and other physiotherapy [5].

To date, one of the most successful mucolytic therapies in CF is rhDNase, which has been found to improve lung function in a broad spectrum of patients [13, 14]. The action of DNase is to degrade the three-dimensional network by mucolysis, or molecular weight disruption.  
30 Combined with other therapies, there are many possibilities for enhancement of potential benefits of this form of therapy [15].

The other target areas mentioned, such as ionic interactions

---

and hydrogen bonds, have received less attention, but are perhaps no less promising.

Agents that affect ionic charge interactions and hydrogen bonds are not true mucolytics because they alter the crosslink density without reducing polymer chain length, the result of which is a common reduction in both elasticity and viscosity [7, 15].

Ionic agents, such as hypertonic saline, are believed to be mucoactive by shielding the fixed charges along the macromolecular core of the mucin polymer, making it less stiff and less extended and thus reducing the number of entanglement crosslinks with neighbouring macromolecules [8]. However, the tolerability and potential for interfering with bacterial killing may limit the value of hypertonic saline as a therapeutic agent.

Nonionic agents such as sugar derivatives reduce the crosslink density of sputum, probably by disrupting the hydrogen bonds between mucin molecules [6]. Among oligosaccharides, neutral dextran, lactose and mannitol have all been considered as potential therapeutic agents [6, 11, 12]. The present inventor with others has shown that low molecular weight neutral dextran (m.w. 4000 or less) is a mucolytic agent, reducing the viscoelasticity and spinnability of CF sputum and improving its mucociliary clearability in *in vitro* testing and that the effects on viscoelasticity and spinnability were concentration-dependent, being greater at 4% than at 0.4% (wt./vol.) of dextran [6]. This improved mucocilliary clearability and reduced viscoelasticity was confirmed in *in vivo* studies [16]. By placing sugar moieties, or oligosaccharides, between mucin-mucin bonds, it is hypothesized that treatment with neutral dextran creates rheologically ineffective mucin-oligomeric sugar bonds, which may lead to the disruption of network crosslinks attributed to hydrogen bonds.

It is hypothesized that agents that might alter more than one type of mucosal bond, such as both the hydrogen bonds and the ionic interactions, may result in improved mucus clearance. The present

inventor has found that one such agent, a charged oligosaccharide, low molecular weight heparin, had a greater mucolytic and mucokinetic capacity than the neutral saccharide polymer, dextran. This was seen both in *in vitro* rheological testing [17] and in excised frog palate clearance measurements [18]. However, heparin is expensive to produce and could potentially have toxic side effects such as pulmonary hemoptysis (bleeding of the tracheobronchial mucosa).

As the mucoactive agents known to date have limitations, there is a need for an improved mucoactive agent to improve mucus viscoelasticity and clearability.

#### **SUMMARY OF THE INVENTION**

The present invention provides an improved mucoactive agent and methods and uses therefor. The improved mucoactive agent is a charged oligosaccharide. Preferably, the charged oligosaccharide is charged dextran. Preferably the charged dextran is dextran sulfate or dextran phosphate. Most preferably, the charged dextran is dextran sulfate. It is herein shown that the charged dextran decreases mucus viscoelasticity and increases mucociliary clearability. The present invention relates to these unexpected findings.

In one embodiment, the present invention relates to a method of decreasing viscoelasticity of mucus from the respiratory tract of an animal by administering to the mucus an effective amount of a charged dextran, preferably dextran sulfate.

In another embodiment, the present invention provides a method of improving mucus clearance in an animal, preferably a human, in need thereof comprising administering to the respiratory tract of the animal an effective amount of a charged dextran, preferably dextran sulfate. The animal, preferably human, in need thereof may have a disease characterized by impaired mucus clearability, mucus retention, and/or mucus hypersecretion, such as cystic fibrosis, chronic bronchitis, bronchitis, bronchiectasis, bronchiolitis, or bronchial asthma, but most preferably cystic fibrosis. In another embodiment, the disease may be an

equine condition such as heaves.

In one embodiment the charged dextran, preferably dextran sulfate, is administered in the form of a pharmaceutical composition. In a preferred embodiment the pharmaceutical composition further comprises  
5 a pharmaceutically acceptable carrier, including without limitation diluents and/or excipients. In another embodiment, the pharmaceutical composition is a topical composition and most preferably an aerosol.

Preferably the pharmaceutical composition comprises between about 6.5 mg/ml to 65 mg/ml of a charged dextran, preferably  
10 dextran sulfate.

In another preferred embodiment the charged dextran, preferably dextran sulfate is administered in a concentration of between about 6.5 mg/ml to 65 mg/ml charged dextran per composition, preferably per aerosol composition and in one embodiment at a dose of about 6 to 8.5  
15 mls, and preferably about 7 to 8 mls. For instance, when administered by aerosol, in one embodiment the dose is preferably administered over a period of about 15 to 30 minutes. In another embodiment the dose is administered from about 1 to 4 times daily.

In another embodiment, the charged dextran, preferably  
20 dextran sulfate, is of low molecular weight, preferably between about 500 (dimer) to about 5000.

Other features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific  
25 examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

30 The invention will now be described in relation to the drawings in which:

**Figure 1** is a bar graph illustrating the effects on tracheal

transepithelial potential difference (PD (-mV) by agar bridge technique) in 7 healthy mongrel dogs after 30-minute Ringer aerosol, and after increasing concentrations of aerosolized DexSO<sub>4</sub> (6.5 mg/ml; 20 mg/ml; and 65 mg/ml) in Ringer vehicle. The PD was significantly more negative for all three concentrations of DexSO<sub>4</sub>. Values are plotted as the mean  $\pm$  SEM.

**Figure 2** is a bar graph illustrating the effect of Dextran sulfate on Tracheal Mucociliary Velocity (TMV) by charcoal particle displacement, in 7 healthy mongrel dogs during and after 30 minutes of Ringer aerosol, and during and after increasing concentrations of aerosolized DexSO<sub>4</sub> (6.5 mg/ml; 20 mg/ml; and 65 mg/ml) in Ringer vehicle. There were no significant differences in TMV with DexSO<sub>4</sub> administration.

**Figure 3** is a bar graph illustrating the effect of dextran sulfate on Tracheal Mucus Viscoelasticity (TMV) as determined by magnetic rheometry, expressed as the average log G\* over 1-100 rad/s, in 7 healthy mongrel dogs during and after 30-minute Ringer aerosol, and during and after increasing concentrations of aerosolized DexSO<sub>4</sub> (6.5 mg/ml; 20 mg/ml; and 65 mg/ml) in Ringer vehicle. DexSO<sub>4</sub> administration resulted in a significant decrease in average log G\* at 6.5 and 65 mg/ml compared with the respective Ringer control.

**Figure 4** is a linear graph illustrating the effect of dextran sulfate on mucus % solids content (%SC of collected airway secretion in 7 healthy mongrel dogs during and after 30-minute Ringer aerosol and increasing concentrations of DexSO<sub>4</sub> (6.5 mg/ml; 20 mg/ml; and 65 mg/ml). Dextran sulfate induced a significant increase in %SC. \* Indicates  $p < 0.05$  versus Ringer-1; \*\* Indicates  $p < 0.01$  versus Ringer-2.

**Figure 5** is a bar graph illustrating the effect of heparin and dextran sulfate on Tracheal Mucus Viscoelasticity (TMV) of sputum from 7 cystic fibrosis human patients as determined by magnetic rheometry, expressed as the average log G\* over 1-100 rad/s after treatment with saline, heparin (MW 6000), Dextran Sulfate (MW 5000, about 17% sulphur



by weight), heparin (dimer, highly (fully) sulfated, H-9267:  $C_{12}H_{13}NO_{19}S_3Na_4$ ), or heparin (dimer, low sulfate, partially de-sulfated H-9142,  $C_{12}H_{18}NO_{13}SNa$ ) to a final concentration of about 8 mg/ml ( or 0.4% wt/vol) of sputum. The highly sulfated heparin dimer showed significant  
5 decrease in viscoelasticity as compared to saline control. The effect was similar to heparin, M.W. 6000. The de-sulfated heparin dimer, on the other hand, showed no significant improvement as compared to the control. Dextran sulfate was even more efficient in increasing viscoelasticity than any of the heparins used.

10 **DETAILED DESCRIPTION OF THE INVENTION**

The present invention describes a method of decreasing the viscoelasticity of mucus, comprising contacting the mucus with a mucoactive agent, a charged dextran, such as dextran phosphate or dextran sulfate, more preferably a dextran sulfate, most preferably a low molecular  
15 weight charged dextran, such as low molecular weight dextran sulfate.

The administration of the mucoactive agent of the invention to the mucus can be done *in vivo* or *in vitro*. Possible *in vitro* applications include, diagnostic purposes, and testing mucus to determine optimum dosage and treatment regimes. For example, a method for  
20 diagnosing an animal with impaired mucus clearance could comprise obtaining a sample of the animal's mucus and treating it *in vitro* with charged dextran, and determining the effect of the charged dextran on the viscoelasticity of the mucus to determine whether the animal may have impaired mucus clearance. Further, a method for determining a dosage  
25 regime of an animal with impaired mucus clearance, could comprise:

- (a) obtaining a mucus sample from the animal;
- (b) subjecting aliquots of the mucus sample to different concentrations of charged dextran;
- (c) measuring the viscoelasticity of each of the aliquots of the  
30 mucus sample after administration of the charged dextran, and

(d) determining the preferred dosage of charged dextran based on comparing the effect of the different concentrations of charged dextran on the viscoelasticity of the mucus sample.

The present invention further describes a method of  
5 improving mucus clearance from the respiratory tract of an animal comprising administering to the animal, an effective amount of a charged dextran of the invention, preferably dextran sulfate.

The present invention further describes a method of  
improving mucus clearance in an animal with impaired mucus clearance,  
10 mucus retention and/or mucus hypersecretion, such as animals with lung diseases or conditions including without limitation: cystic fibrosis, chronic bronchitis, bronchitis, bronchiectasis, bronchiolitis (diffuse panbronchiolitis) or bronchial asthma, comprising administering to the animal an effective amount of a charged dextran, preferably dextran  
15 sulfate, to an animal in need thereof.

In the studies presented herein low molecular weight dextran sulfate (about m.w. 5000 or less) administered to the respiratory tract in aerosol form through inhalation has been specifically shown to reduce viscoelasticity and increase mucociliary clearability of mucus in the  
20 respiratory tract of healthy dogs. It has also been shown to reduce viscoelasticity of mucus obtained from human patients with cystic fibrosis.

The present invention also describes pharmaceutical compositions which can be used in the methods of the invention comprising the mucoactive agent of the invention and a pharmaceutically  
25 acceptable carrier and may include, diluents and excipients.

"Mucoactive agent" as used herein refers to an agent which can reduce the viscoelasticity of mucus and/or improve or potentially improve the clearance of mucus from the respiratory tract. Preferably, the mucoactive agent of the invention is a charged dextran, preferably a low  
30 molecular weight charged dextran.

Examples of charged dextrans suitable for use in the present invention include without limitation, dextran phosphate and dextran

sulfate. Preferably, the charged dextran is dextran sulfate. Charged dextran as used herein may include fully or partially charged dextran. For example, when dextran phosphate or dextran sulfate is used, the degree of phosphorylation or sulfation can vary from low (10-20% of monomer units) to high (fully sulfated or phosphorylated - one sulfate per sugar residue]. Low molecular weight charged dextran, such as low molecular weight dextran sulfate as used herein means charged dextran or dextran sulfate, as the case may be, with a molecular weight of between about 500 (dimer) and 5000.

10 "Animal" as used herein is any living organism which has a respiratory tract and secretes mucus into the respiratory tract and is susceptible to conditions or diseases involving impaired mucus clearance. Preferably, the animals are mammals, preferably rats, mice, horses, dogs, or humans, and most preferably dogs or humans.

15 "Effective amount" as used herein means an amount of the mucoactive agent, effective at dosages and for periods of time necessary to achieve the desired result. An effective amount may vary according to factors known in the art, such as the disease state, age, sex, and weight of the animal being treated. Although particular dosage regimes are described in the examples herein, a person skilled in the art would appreciate that the dosage regime may be altered to provide optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

25 As preferred administration is by aerosol, dosages by aerosol are generally indicated by concentration of the agent in the nebulizer, and the dose is regulated by the ventilation rate (volume of air per minute) of the animal, which is roughly proportional to body weight. For example, the mucoactive agents of the invention are preferably administered in a concentration of between about 6.5 mg/ml to 65 mg/ml mucoactive agent per composition administered, preferably per aerosol composition and in one embodiment at a dose of about 6 to 8.5 mls (i.e. from about 39 mg to

171  
SCANNED  
6

552.5 mg of mucoactive agent), and preferably about 7 to 8 mls. For instance, when administered by aerosol through inhalation, in one embodiment the dose is preferably administered over a period of about 15 to 30 minutes. In another embodiment the dose is administered from  
5 about 1 to 4 times daily.

"Clearance and clearability" as used herein refers to the ability of the mucus to be cleared from the respiratory tract of an animal. This can include without limitation to mucociliary clearance or cough.

The mucoactive agents of the invention may be administered  
10 by topical administration to the mucus or respiratory tract of the animal in a known manner, such as in the form of an aqueous aerosol, dry powder inhaler, metered dose inhaler (with non-aqueous propellant), or direct topical instillation (to intubated patients, or through nasal or sinus irrigation). Most preferably administration is in the form of an aerosol by  
15 inhalation.

Depending on the route of administration, the mucoactive agents of the invention can be administered in the form of pharmaceutical compositions which may also comprise pharmaceutically acceptable carriers, diluents and excipients. Examples of suitable pharmaceutical  
20 carriers which can be used in the invention are Ringer's solution, water, and sterile saline (0.9% NaCl). The pharmaceutical compositions of the invention can be prepared by *per se* known methods for the preparation of pharmaceutically acceptable compositions. Suitable methods and pharmaceutical carriers which can be used in the preparation of  
25 pharmaceutical compositions of the invention are described in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA, 1985).

Preferably the pharmaceutical composition comprises between about 6.5 mg/ml to about 65 mg/ml of charged dextran, preferably  
30 dextran sulfate.

The present inventor has found that charged dextran, i.e. dextran sulfate, had significant effects on mucus viscoelasticity in *in vivo*

testing, and administration of dextran sulfate by aerosol could increase the rate of mucociliary clearance. Since a charged macromolecule applied to the mucosal surface could alter epithelial ion currents, the changes in tracheal potential difference as an index of epithelial ion transport [19] was also studied. It was shown that dextran sulfate exhibited significant mucolytic capacity. It is believed that the dextran sulfate exerts its effect by modification of both bulk rheological properties and surface effects. As a charged oligosaccharide, dextran sulfate is believed to interfere with hydrogen bond interactions between mucin macromolecules, as well as with ionic interactions in the mucous gel. The net result is a stimulation of mucociliary clearance.

The use of a charged dextran, such as dextran sulfate, as a mucoactive agent has the advantage of being considerably cheaper to produce than heparin or other charged oligosaccharides. Also, dextrans have antimicrobial activities, this with the addition of mucoactive effects has added benefits in the treatment of patients with airway infections.

Both ionic and nonionic approaches to mucoactive therapy show good promise at selectively improving mucociliary clearance. The use of a charged dextran, such as dextran sulfate, as a mucoactive agent can be combined with other therapies, such as Pulmozyme (rhDNase) and/or N-acetylcysteine derivatives in the treatment of diseases with impaired mucus clearance, such as cystic fibrosis, bronchitis, chronic bronchitis, bronchiectasis, bronchiolitis, and bronchial asthma. For instance, the methods of the present invention using charged dextran, could be combined with a true mucolytic agent (e.g. rhDNase or N-acetylcysteine) that reduces molecular chain length, to improve both mucociliary and cough clearability [8, 15].

The following non-limiting examples are illustrative of the present invention:

#### EXAMPLES

##### Example 1

The following study was conducted to determine the effect of

a charged dextran, dextran sulfate, on the viscoelasticity of mucus and the clearability of mucus from the respiratory tract of healthy dogs.

## **MATERIALS AND METHODS**

### **Study Design**

5                Seven healthy mongrel dogs (6 male/1 female ), weight 21 -  
28 kg, were studied. The dogs were anesthetized with sodium  
pentobarbital (*ca* 30 mg/kg i.v., supplemented as required) and intubated  
with a cuffed endotracheal tube. They were administered Ringer aerosol  
first, followed by 6.5 mg/ml dextran sulfate, 20 mg/ml dextran sulfate, and  
10 65 mg/ml dextran sulfate by aerosol. Each aerosolization was of 30  
minutes duration, with a rest period of 30 minutes before the beginning of  
the next aerosol delivery. The aerosols were generated and delivered by a  
Pari LC STAR nebulizer using an air flow rate of 8 l/min, which results in  
an output of 0.58 ml/min and particles of 2.0  $\mu$ m mass median diameter.  
15 The nebulizer was loaded in each case with 10 ml of solution. The amount  
of solution remaining in the nebulizer after 30 minutes was recorded. A  
T-tube connection was provided to the endotracheal tube during aerosol  
delivery to ensure a minimal deadspace for ventilation and adequate  
delivery of the aerosol. The dogs breathed spontaneously throughout the  
20 experiment.

Tracheal mucus velocity (TMV) and tracheal potential  
difference (PD) was measured, and mucus samples were collected for each  
concentration of delivered drug. TMV was measured twice for each dose,  
i.e. during aerosolization, between 15 and 25 minutes from the start of  
25 aerosol delivery (designated as period-1), and 10-20 minutes after  
completion of aerosolization (designated as period-2). PD was measured  
during the period 5 to 10 minutes following each aerosol. Mucus was  
collected twice for each aerosol, once immediately after 30 minutes of  
aerosolization and a second time after an additional 30 minutes of  
30 aerosolization and a second time after an additional 30 minutes of  
spontaneous breathing.

All samples of dog mucus collected from endotracheal tubes were placed in 1.5 ml Eppendorf tubes for measurement of viscoelasticity by magnetic rheometry. After initial rheological testing, the mucus samples were preserved at -80°C for subsequent analysis of collection rate and solids content.

Dextran sulfate, sodium salt (DexSO<sub>4</sub>) was obtained from Sigma-Aldrich, St. Louis, MO (catalog# D7037, lot# 88HO725) for use in this *in vivo* test. Its nominal molecular weight was 5000, and the sulfur content was 17.7%. DexSO<sub>4</sub> was dissolved in Ringer solution as vehicle. Ringer solution comprises NaCl, as well as KCl and CaCl<sub>2</sub> in approximate physiological concentration as found in plasma.

**Transepithelial Potential Difference (PD, -mV):** PD was measured by using two flexible microelectrodes (agar bridges of PE 160 size) saturated with KCl connected to calomel half cells, one for reference and the other for testing. These were connected to the high impedance input of a grounded pH meter (Fisher Accumet 925). The reference probe was inserted subcutaneously into the hind leg of the anesthetized dog in a supine position. The measurement probe was guided by bronchoscopy and carefully placed in contact with the epithelium *ca* 2 cm above the main carina. Care was taken to position the measurement tip to make the slightest contact with the mucosal surface. The PD value was recorded when a steady state, value was achieved and remained stable for a least 30 seconds.

**Tracheal Mucociliary Velocity (TMV, mm/min):** TMV was determined by observing the rate of charcoal marker particle transport in the lower trachea [20]. Under bronchoscopic visualization, *ca*, 5 µL of a charcoal suspension (Charac-50 diluted in Ringer's 1: 10) was deposited on a lateral surface of the lower trachea 1-2 cm above the carina, and the rate of cephalad progression of the leading edge of the charcoal spot was monitored over the course of 10 minutes by gradually withdrawing the bronchoscope and recording its position relative to the endotracheal tube.

TMV was determined twice for each aerosolization period, once during the aerosol, starting after 15 minutes had elapsed, and a second time starting about 10 minutes after the aerosolization had been completed. A T-connector with a seal was employed to allow for bronchoscopic  
5 visualization during the delivery of the aerosols.

**Mucus Collection Weight (MCW, mg/30 min):** Tracheal mucus was collected by the endotracheal tube (ETT) method, which involves the removal of mucus adherent to the ETT after extubation [24]. Mucus collections were performed twice after each aerosol, once by  
10 immediately removing the ETT following aerosol inhalation, and the second 30 minute after inhalation, after re-installing a clean ETT. The mucus samples, which had been frozen, were thawed and weighed by microbalance, to determine MCW, an index of flux, and indirectly of the rate of secretion [20].

**Mucus Viscoelasticity Measurements:** The magnetic microrheometer technique was used to measure the viscosity and elasticity of the dog mucus samples [21]. A 100  $\mu\text{m}$  steel ball was positioned in a 5-10  $\mu\text{L}$  sample of mucus, and the motion of this sphere under the influence of an oscillating electromagnetic field gradient was used to  
15 determine the rheological properties of the mucus. The image of the steel ball was projected via a microscope onto a pair of photocells, whose output was amplified and transmitted to an oscilloscope. By plotting the displacement of the ball against the magnetic driving force, the viscoelastic properties of the mucus were ascertained.  
20

The parameters of mucus viscoelasticity determined were the rigidity index or mechanical impedance, i.e.  $G^*$ , reported here on a log scale, expressing the average vector sum of "viscosity + elasticity" over the frequency range 1-100 rad/s, and  $\tan \delta$ , the mechanical loss tangent, expressing the ratio of viscous to elastic deformation [21]. These  
25 viscoelastic parameters can be used to predict mucus clearability by ciliary and cough mechanisms, based on the measured rheological properties and  
30

---



observations of clearance from model studies [22].

**Solids content** (wet:dry weight ratio): A drying apparatus and microbalance were used to calculate the dry weight and wet weight of the collected secretion, from which the percent solids content (%SC) was calculated. The mucus samples, free of oil, were weighed on previously weighed glass slides. The samples were then dried in a microwave oven (750 W for 30 minutes) and allowed to cool. These dried samples were then reweighed, and % SC was calculated from ratio of dry to wet weight [23].

**Statistical analysis:** Data from each protocol are presented as mean  $\pm$  standard error (SE) of the mean. To analyze the significance of changes in tracheal mucociliary velocity, potential difference, solids content, and log  $G^*$  at 1-100 rad/s after each dextran aerosol, the data from each dog were compared with its own control vehicle data. Equality of means was tested by analysis of variance (ANOVA); post hoc analysis of changes from baseline was determined by the two-tailed, paired t-test. The StatView statistical package (Abacus Concepts, Palo Alto, CA) was used to carry out these analyses.

## **RESULTS**

All seven dogs completely finished each protocol without significant cough or other side effects during dextran sulfate inhalation, and the bronchial mucosal appearance remained normal.

The osmotic pressures of the  $\text{DexSO}_4$  solutions were determined by means of a Wescor model 5500 vapor pressure osmometer. The excess osmolarity over Ringer's was as follows: 6.5 mg/ml: 15 mOsm; 20 mg/ml: 45 mOsm; 65 mg/ml: 141 mOsm. The delivered volume of aerosol from the Pari LC STAR nebulizer averaged  $9.0 \pm 0.8$  ml, and did not change with increasing dose.

Immediately following 30 minutes of the low-dose  $\text{DexSO}_4$  aerosol (6.5 mg/ml) and after administration of the second dose (20 mg/ml) and the highest concentration (65 mg/ml), PD increased

significantly compared with Ringer control (6.5 mg/ml:  $p = 0.0005$ ; 20 mg/ml:  $p = 0.0056$ ; 65 mg/ml:  $p = 0.0067$ ). The maximal change in PD was seen for the highest DexSO<sub>4</sub> concentration, a mean increase of 9.86 mV at 65 mg/ml (Figure 1). The differences between the three dextran  
5 concentrations were not significant.

There was no significant change in mucociliary velocity. For the first dose of DexSO<sub>4</sub>, at 6.5 mg/ml, a non-significant increase in TMV to 128% of baseline ( $p=0.066$ ) was observed. Thereafter, TMV remained stable, not differing from baseline with increasing DexSO<sub>4</sub> concentration  
10 (Figure 2).

Tracheal mucus viscoelasticity decreased progressively and significantly with increasing concentration of aerosolized DexSO<sub>4</sub>. At the highest dose, during 65 mg/ml DexSO<sub>4</sub>, the mean decrease in average log G\* was 0.42 log units, or a factor of 2.61 ( $p=0.021$ ) (Figure 3). The changes in  
15 log G\* at the three measurement frequencies (1, 10 and 100 rad/s) were all parallel on a logarithmic basis. There were no significant changes in the mucus recoil parameter,  $\tan \delta$ , with DexSO<sub>4</sub> administration.

There was no change in mucus collection weight (MCW, mg/30 min) with increasing DexSO<sub>4</sub> concentration, based on the wet  
20 weight of collected tracheal fluid (Ringer-1:  $5.76 \pm 0.60$  mg; 6.5 mg/ml-1 DexSO<sub>4</sub>:  $4.35 \pm 0.67$  mg; 20 mg/ml-1:  $4.47 \pm 0.59$  mg; 65 mg/ml-1:  $5.64 \pm 1.14$  mg). The solids content (%SC) of collected fluid, i.e. for the mucus that accumulated on the ETT during aerosol inhalation, gradually increased during successive 30-minute DexSO<sub>4</sub> aerosols (from  $6.16 \pm 0.20\%$  at  
25 Ringer-1 to  $9.27 \pm 1.02\%$  at 65 mg/ml-1 DexSO<sub>4</sub>,  $p = 0.042$ ; and from  $6.87 \pm 0.92\%$  at Ringer-2 to  $10.78 \pm 1.27\%$  at 65 mg/ml-2 DexSO<sub>4</sub>,  $p = 0.009$ ) (Figure 4).

There were significant correlations between mean log G\* and PD ( $p = 0.0001$ ), between log G\* and %SC ( $p = 0.028$ ), and between PD and %  
30 SC ( $p = 0.005$ ).

## DISCUSSION

It has been shown that treatment of sputum with sodium chloride increases ciliary transportability on the mucus-depleted bovine trachea [7] and also stimulates lung mucociliary clearance in CF patients, asthmatics, and healthy subjects [24, 25]. It has been shown that agents that alter the ionic interactions or the hydrogen bonding of the mucus gel can produce potentially beneficial effects on mucus clearability. This was found to be the case with hypertonic saline [8, 26, 27], and with dextran [6, 16]. Recently, agents that might alter both the hydrogen bonds and the ionic interactions have been studied. It was found that one such agent - the charged oligosaccharide, low molecular weight heparin [17, 18] - had a greater mucolytic and mucokinetic capacity than the neutral saccharide polymer, dextran. The initial conclusion was that heparin decreases mucus viscoelasticity by 1) interaction of its negative charge on the amino groups of the mucin molecule, thereby reducing its entanglement with neighboring sulfate groups, and/or 2) interfering with intermolecular hydrogen bonding due to its short-chain oligosaccharide character (similar to dextran), and/or 3) ionic shielding effects of sodium and heparin on the polyionic moieties of the mucin molecule.

In the present study, it was investigated how low molecular weight dextran sulfate, as a charged oligosaccharide based on dextran, affects tracheal mucus rheology and mucociliary clearance in healthy dogs. Tracheal PD was altered consistently and significantly to higher negative values after  $\text{DexSO}_4$  administration. Changes in PD reflect changes in epithelial ion transport or altered integrity [19]. An increase in negative PD value could indicate an increase in epithelial resistance, but in a healthy dog this is unlikely. It more likely indicates an increase in the driving potential for luminal ion transfer, either increased  $\text{Cl}$  ion secretion or sodium absorption. Given the excess osmolarity of the fluid delivered to the luminal surface, the increase in tracheal PD seen with  $\text{DexSO}_4$  suggests an increase in the driving potential for chloride-linked water transfer, indicating that an osmotic mechanism, as suggested by Winters and Yeates

[28], was active.

At the same time, there was a progressive and significant decrease in tracheal mucus rigidity with DexSO<sub>4</sub> administration compared with the Ringer vehicle. This decrease in mucus rigidity index is consistent with enhanced mucus clearability by ciliary and cough mechanisms [22]. Although no vehicle control experiment was included in this protocol, previous studies have indicated that repeated administration of Ringer's solution results in no significant change in either TMV or log G\* over the course of 4 hours [16]. In the present study, these was a correlation between log G\* and PD, with G\* decreasing as PD increased. There was also a significant correlation between log G\* and %SC, indicating that the viscoelastic effect was proportional to the amount of DexSO<sub>4</sub> delivered and still resident in the airway fluid. In other studies, correlations between the change in PD and the change in mucus viscoelasticity in dogs receiving Nacystelyn aerosol [29] and in mice administered methacholine or uridine triphosphate [30] have been reported. These findings support a commonality in the relationship between the stimulation of transepithelial chloride transport by these diverse agents and hydration of the mucous gel.

In a previous study [16] the TMV was measured 5-15 minutes after each aerosolization, and thus the peak TMV may have been missed resulting in an underestimation of the maximal drug effect. Accordingly, the protocol of the present study was modified to measure TMV both during and after aerosolization in order to be more certain about this issue. In the present study, using aerosolized DexSO<sub>4</sub>, it was found that there was no significant difference in the TMV measured during aerosolization compared with the TMV measured 5-15 minutes after. The fact that no significant increase in TMV was seen in these healthy dogs, despite the improvement in mucus rheological properties, might be ascribed to their healthy status and the probable fact that their TMV was already near optimal. More noticeable improvements in clearance

associated with a similar change in mucus rheology might be revealed by studies in a pathological animal model [31].

Based on the wet weight results, DexSO<sub>4</sub> aerosol did not induce an increase of the volume output of tracheal fluid in this dose-dependency experiment, i.e. it did not cause hypersecretion. This was a concern because the protocol involved delivery of a hypertonic aerosol. The solids content of the secretion (%SC) that accumulated on the endotracheal tube cuff during the 30 minutes of aerosolization increased in proportion to the concentration of the delivered dextran sulfate. This increase in nonevaporable solids content is unlikely due to an increased concentration of macromolecules in the mucous gel, since this would lead to an increase in rigidity index, which was opposite to what was observed. In fact the solids content correlated inversely with log G\*. The most likely explanation for the excess solids content in the collected secretion is that it contained dextran sulfate which had accumulated in the mucus during aerosolization and did not diffuse away at least for the 60-minute time course between successive DexSO<sub>4</sub> administrations. In a previous study, it was reported that neutral dextran had a significant retention time in the mucus, with a half-life perhaps of the order of a half-hour [16]. This is in sharp contrast to the effects of hypertonic saline aerosol, where less than 30 minutes after delivery of 12% NaCl, no elevation of sodium ion content or excess solids content could be detected [25, 27]. Retention of dextran sulfate in the mucus layer beyond the immediate period of aerosolization, and thus prolongation of the rheological benefit, would be a distinct advantage in terms of therapy.

The present study demonstrates that low molecular weight dextran sulfate applied *in vivo* significantly reduces the viscoelastic modulus of healthy dog mucus, and increases the predicted mucociliary and cough clearance at a half-log lower concentration range than was observed for neutral dextran [6].

It is also similar to low molecular weight heparin, which

from preliminary considerations is effective at a half-log lower concentration than neutral dextran [32].

Although tracheal mucociliary clearance did not significantly increase in these healthy dogs, it did not diminish, and there was no indication of any deleterious effects. The osmotic burden of the delivered aerosol was modest.

Although, no toxic effects of dextran sulfate were observed in the present study, In other laboratories, DexSO<sub>4</sub> has been used to induce experimental colitis in rodents [33]; the mechanism probably involves erosion of the protective intestinal mucus layer. To induce colitis, DexSO<sub>4</sub> (m.w. 40,000) was administered to rats at 5% concentration in drinking water for 7 days. However, dextran sulfate (m.w. 7000) has also been administered orally to human subjects, with little anticoagulant effect because of its poor absorbability, and no other apparent safety concerns [34]. The potential of dextran sulfate as a therapy with no or minimal toxic effects is a question of dose, route of administration, molecular weight, and charge.

In summary, it can be concluded that delivery of aerosolized dextran sulfate to canine airways leads to reduced viscoelasticity and improved clearability of the tracheal mucus. It thus may be of benefit in patients with CF lung disease or other respiratory diseases where mucus retention is an important feature.

## **EXAMPLE 2**

The following study was conducted to compare the affect of dextran sulfate and heparin on the viscoelasticity of mucus and the clearability of mucus from the respiratory tract.

(a) *In vitro* Sputum from 7 cystic fibrosis human patients were measured with regards to viscoelasticity after treatment with saline, heparin (MW~6000), dextran sulfate (MW~5000), heparin (dimer, highly sulfated), or heparin (dimer, de-sulfated) in accordance with the protocols for measuring viscoelasticity described in Example 1. The final

concentration of oligosaccharide or disaccharide in the sputum was 8 mg/ml.

The results of the study are illustrated in Figure 5 where it can be seen that the highly sulfated heparin dimer showed significant decrease in viscoelasticity as compared to saline control. The effect was similar to heparin, MW 6000. The de-sulfated heparin dimer, on the other hand, showed no significant improvement as compared to the control. Dextran sulfate was even more efficient in increasing viscoelasticity than either heparin, MW 6000 or the highly sulfated heparin dimer.

(b) *In vivo* Seven healthy dogs were anesthetized, intubated and treated via aerosol with heparin sodium (MW 5000-6000) or dextran sulfate (MW 5000) and mucus viscoelasticity, transepithelial potential difference (PD) and tracheal mucus velocity (TMV) were determined, in accordance with the protocols described in Example 1 above. Non-lactated Ringer's solution was used as control. Heparin and dextran sulfate showed similar effects on mucus viscoelasticity and TMV. For heparin at 6.5 mg/ml, there was a significant decrease in PD, to 55.1% of control, and at this same dose, mucus viscoelasticity ( $G^*$ ) was significantly decreased to 36% of control. These changes were accompanied by a nonsignificant, upward trend in TMV, to approximately 130% of control. However, changes might be even more pronounced in animals with initially rigid mucus.

The above studies illustrate that dextran sulfate is potentially more effective than heparin as a mucoactive agent. Further, dextran sulfate is less expensive than heparin. No toxic affects were observed at the concentrations employed in these studies.

While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.





**FULL CITATIONS FOR REFERENCES REFERRED TO IN THE SPECIFICATION**

1. King, M., and B.K. Rubin. 1996. Mucus physiology and pathophysiology: Therapeutic aspects. Chapter 13 of: Derenne, J.P., W.A. Whitelaw, and T. Similowski, eds. *Acute Respiratory Failure in COPD (Lung Biology in Health and Disease Series)* Marcel Dekker, New York, 391-411.
2. Rubin, B.K., R.P. Tomkiewicz, and M. King. 1997. Mucoactive agents: Old and new. Chapter 7 of: Wilmott, R.W., ed. *The Pediatric Lung*. Birkhduser, Basel, 155-179.
3. Sheffner, A.L. 1963. The reduction *in vitro* in viscosity of mucoprotein solutions by a new mucolytic agent, N-acetylcysteine. *Ann. N. Y. Acad. Sci.* 106:298-310.
4. Dasgupta, B., and M. King. 1996. Reduction in viscoelasticity of cystic fibrosis sputum *in vitro* with combined treatment by Nacystelyn and rhDNase. *Pediatr. Pulmonol.* 22:161-166.
5. App, E.M., R. Kieselmann, D. Reinhardt, H. Lindemann, B. Dasgupta, M. King, and P. Brand. 1998. Sputum rheology changes in cystic fibrosis lung disease following two different types of physiotherapy: Flutter *vs.* autogenic drainage. *Chest* 114:171-177.
6. Feng, W., H. Garrett, D.P. Speert, and M. King. 1998. Improved clearability of cystic fibrosis sputum with dextran treatment *in vitro*. *Am. J. Respir. Crit. Care Med.* 157:710-714.
7. Wills, P.J., R.L. Hall, W.M. Chan, and P.J. Cole. 1997. Sodium chloride increases the ciliary transportability of cystic fibrosis and

bronchiectasis sputum on the mucus-depleted bovine trachea. *J. Clin. Invest.* 99:9-13.

8. King, M., B. Dasgupta, R.P. Tomkiewicz, and N.E. Brown. 1997. Rheology of cystic fibrosis sputum after in *vitro* treatment with hypertonic saline alone and in combination with rhDNase. *Am. J. Respir. Crit. Care Med.* 156:173-177.
9. Shak, S., D.J. Capon, R. Hellmiss, S.A. Marsters, and C.L. Baker. 1990. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. *Proc. Natl. Acad. Sci. U.S.A.* 87:9188- 9192.
10. Vasconcellos, C.A., P.G. Allen, M. Wohl, J.M. Drazen, and P.A. Janmey. 1994. Reduction in sputum viscosity of cystic fibrosis sputum in *vitro* by gelsolin. *Science* 263:969-971.
11. Daviskas, E., S.D. Anderson, J.D. Brannan, H.K. Chan, S. Eberl, and G. Bautovich. 1997. Inhalation of dry-powder mannitol increases mucociliary clearance. *Eur. Respir. J.* 10:2449-2454.
12. Shibuya, Y., P.J. Wills, S. Kitamura, and P.J. Cole. 1997. The effects of lactose on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum. *Eur. Respir. J.* 10:321s.
13. Fuchs, H.J., D.S. Borowitz, D.H. Christiansen, E.M. Morris, M.L. Nash, B.W. Ramsey, B.J. Rosenstein, A.L. Smith, and M.E. Wohl. 1994. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in cystic fibrosis. *N. Engl. J. Med.* 33:637-648.
14. Ranasinha, C., B. Assoufi, S. Shak, D. Christiansen, H. Fuchs, D. Empey, D. Geddes, and M. Hodson. 1993. Efficacy and safety of

short-term administration of aerosolized recombinant human DNase I in adults with stable stage cystic fibrosis. *Lancet* 342: 199-202.

15. King, M., and B.K. Rubin. 1999. Mucus controlling agents: Past and present. In: Rau, J.L., ed. *Aerosolized Drugs for the Respiratory Tract. Respir Care Clinics N Amer.* in press.
16. Feng, W., S. Nakamura, E. Sudo, M.M. Lee, A. Shao, and M. King. 1999. Effects of dextran on tracheal mucociliary velocity in dogs in vivo. *Pulm. Pharmacol. Ther.* 12:35-41.
17. Lee, M.M., and M. King. 1998. Effect of low molecular weight heparin on the elasticity of dog mucus. *Clin. Invest Med.* 21:S 102.
18. Lee MM, H. Garrett, E. Sudo, W.A. Boyd, and M. King. 1998. Mucociliary clearance increase due to low molecular weight heparin. *Pediatr. Pulmonol.* 386:S 17.
19. App, E.M., J.G. Zayas, and M. King. 1993, Rheology of mucus and epithelial potential difference: Small airways vs. trachea. *Eur. Respir, J.* 6: 67-75.
20. King, M., S. Kelly, and M. Cosio. 1985. Alteration of airway reactivity by mucus. *Respiration Physiol.* 62:47-59.
21. King, M. 1988. Magnetic microrheometer. In: Braga, P.C., and L. Allegra, eds. *Methods in Bronchial Mucology*. Raven Press, New York, 73-83.
22. King, M. 1987. Role of mucus viscoelasticity in cough clearance. *Biorheology* 24: 589-597.

23. Rubin, B.K., O. Ramirez, J.G. Zayas, B. Finegan, and M. King. 1990. Collection and analysis of respiratory mucus from individuals without lung disease. *Am. Rev. Respir. Dis.* 141:1040-1043.
24. Daviskas, E., S.D. Anderson, I. Gonda, S. Eberl, S. Meikle, J.P. Seale, and G. Bautovich. 1996. Inhalation of hypertonic saline aerosol enhances mucociliary clearance in asthmatic and healthy subjects. *Eur. Respir. J.* 9:725-732.
25. Robinson, M., A. Hemming, J.A. Regnis, D.L. Bailey, M. King, W. Feng, G.J. Bautovich, and P.T.P. Bye. 1998. Improved mucociliary clearance following nebulisation with hypertonic saline in adults with cystic fibrosis. In: Baum, G., ed. *Cilia, Mucus and Mucociliary Interactions*. Marcel Dekker, New York, 265-280.
26. Tomkiewicz, R.P., W.A. Boyd, W. Feng, E.M. App, B.K. Rubin, and M. King. 1997. Tracheal clearance and mucus rheology in healthy dogs after aerosolization of 3% and 7% hypertonic saline. *Am. J. Respir. Crit. Care Med.* 155:A780.
27. Nakamura S, Sudo E, W. Feng, M.M. Lee, W.A. Boyd, and M. King. 1998. Effects of hypertonic saline aerosolization on tracheal mucus clearance and mucus rheology in healthy dogs. *Eur. Respir. J.* 12(S28): 180s.
28. Winters, S.L., and D.B. Yeates. 1997. Role of hydration, sodium, and chloride in regulation of canine mucociliary transport system. *J. Appl. Physiol.* 83:1360-1369.
29. Tomkiewicz, R.P., E.M.App, G.T. De Sanctis, M. Coffiner, P. Maes, B.K. Rubin, and M. King. 1995. A comparison of a new mucolytic N-acetylcysteine L-lysinate with N-acetylcysteine: Airway epithelial function and mucus changes in dog. *Pulm. Pharmacol.* 8:259-265.

30. Sudo, E., M.M. Lee, W.A. Boyd, and M. King. 1998. Effect of methacholine and uridine-5' triphosphate on tracheal mucus rheology in mice. *Pediatr. Pulmonol.* S 17:229.
31. Tai, S., H. Kai, T. Kido, Y. Isohama, K. Takahama, and T. Miyata. 1997. Effect of human neutrophil elastase on tracheal mucociliary transport in anesthetized quails. *Jpn. J. Pharmacol.* 75:439-442.
32. King, M., A. Ghahary, R. Franklin, M. Hirji, D. Malchenko, W.A. Boyd, H. Garrett, and M.M. Lee. 1999. Studies on aerosolized low mol. wt. heparin as a mucokinetic agent in dogs. *Am. J. Respir. Crit. Care Med.* 159:A474.
33. Bjork, S., E. Jennische, A. Dahlstrom, and H. Ahlman. 1997. Influence of topical rectal application of drugs on dextran sulfate-induced colitis in rats. *Dig. Dis. Sci.* 42:824-832.
34. Lorentsen, K.J., C.W. Hendrix, J.M. Collins, D.M. Kornhauser, B.G. Petty, R.W. Klecker, C. Flexner, R.H. Eckel, and P.S. Lietman. 1989. Dextran sulfate is poorly absorbed after oral administration. *Ann. Int. Med.* 111: 561-566.

## DETAILED FIGURE LEGENDS

### Figure 1

The effects on tracheal transepithelial potential difference (PD by agar bridge technique) in 7 dogs after 30-minute Ringer aerosol, and after increasing concentrations of aerosolized DexSO<sub>4</sub> in Ringer vehicle. The PD was significantly more negative for all three concentrations of DexSO<sub>4</sub>. Values are plotted as the mean  $\pm$  SEM.

### Figure 2

Tracheal mucociliary velocity, TMV by charcoal particle displacement, in 7 dogs during and after 30 minute Ringer aerosol, and during and after increasing concentrations of aerosolized DexSO<sub>4</sub> in Ringer vehicle. There were no significant differences in TMV with DexSO<sub>4</sub> administration.

### Figure 3

Tracheal mucus viscoelasticity as determined by magnetic rheometry, expressed as the average log G\* over 1-100 rad/s, in 7 dogs during and after 30-minute Ringer aerosol, and during and after increasing concentrations of aerosolized DexSO<sub>4</sub> in Ringer vehicle. DexSO<sub>4</sub> administration resulted in a significant decrease in average log G\* at 6.5 and 65 mg/ml compared with the respective Ringer control.

### Figure 4

Solids content (%SQ of collected airway secretion in 7 dogs during and after 30-minute Ringer aerosol and increasing concentrations of DexSO<sub>4</sub>- Dextran sulfate induced a significant increase in %SC. \* Indicates p < 0.05 versus Ringer-1; \*\* Indicates p < 0.01 versus Ringer-2.

### Figure 5

Tracheal mucus viscoelasticity of sputum from 7 cystic

fibrosis patients as determined by magnetic rheometry, expressed as the average  $\log G^*$  over 1-100 rad/s after treatment with saline, heparin (MW-6000), dextran sulfate (MW-5000), heparin dimer (highly sulfated), or heparin dimer (de-sulfated). The highly sulfated heparin dimer showed  
5 significant decrease in viscoelasticity as compared to saline control. The effect was similar to heparin, MW 6000. The de-sulfated heparin dimer, on the other hand, showed no significant improvement as compared to the control. Dextran sulfate was even more efficient in increasing viscoelasticity than heparin, MW 6000.

005230" 46531960

**What is claimed is:**

1. A method of decreasing viscoelasticity of respiratory tract mucus comprising administering to the mucus an effective amount of charged dextran.
- 5 2. The method of claim 1 wherein the charged dextran is a low molecular weight dextran.
3. The method of claim 2 wherein the molecular weight of the dextran is from 500 to 5000.
4. The method of claim 1 wherein the charged dextran is  
10 dextran phosphate or dextran sulfate.
5. The method of claim 4 wherein the charged dextran is dextran sulfate.
6. The method of claim 3 wherein the charged dextran is dextran sulfate.
- 15 7. The method of claim 1 for improving mucus clearance from the respiratory tract of an animal in need thereof comprising administering to the animal an effective amount of charged dextran.
8. The method of claim 7 for treating an animal with impaired mucus clearance.
- 20 9. The method of claim 8 wherein the impaired mucus clearance is associated with a lung disease.
10. The method of claim 9 wherein the lung disease is selected from the group consisting of: cystic fibrosis, chronic bronchitis, brronchitis,



bronchiectasis, bronchiolitis and bronchial asthma.

11. The method of claim 8 wherein the animal is a horse and the disease is heaves.

12. The method of claim 10 wherein the animal is human.

5 13. The method of claim 12 wherein the disease is cystic fibrosis.

14. The method of claim 7 wherein the effective amount is between about 39 mg to about 552.5 mg.

15. The method of claim 7 wherein the charged dextran is administered to the respiratory tract of the animal in the form of a pharmaceutical composition comprising a charged dextran and a pharmaceutically acceptable carrier.

16. The method of claim 15 wherein the pharmaceutical composition is an aerosol and is administered through inhalation.

17. The method of claim 16 wherein the charged dextran is low molecular weight charged dextran.

18. The method of claim 17 wherein the molecular weight of the charged dextran is from 500 to 5000.

19. The method of claim 18 wherein the charged dextran is dextran sulfate.

20 20. A pharmaceutical composition for decreasing the viscoelasticity of mucus comprising a charged dextran and a pharmaceutically acceptable carrier.

21. The pharmaceutical composition of claim 20 wherein the charged dextran is a low molecular weight dextran.

22. The pharmaceutical composition of claim 21 wherein the molecular weight of the charged dextran is from 500 to 5000.

5 23. The pharmaceutical composition of claim 22 wherein the charged dextran is dextran sulfate.

24. The pharmaceutical composition of claim 20 wherein the composition comprises between about 6.5 mg/ml to about 65 mg/ml of dextran sulfate/ml of the composition.

10 25. The pharmaceutical composition of claim 17 wherein the composition is a topical composition.

26. The pharmaceutical composition of claim 17 wherein the composition is an aerosol.

27. The method of claim 1 for diagnosing an animal with  
15 impaired mucus clearance comprising obtaining a sample of the animal's mucus and treating it *in vitro* with charged dextran, determining the effect of the charged dextran on the viscoelasticity of the mucus to determine whether the animal may have impaired mucus clearance.

28. The method of claim 1 for determining a dosage regime of  
20 an animal with impaired mucus clearance, comprising:

- (a) obtaining a mucus sample from the animal;
- (b) subjecting aliquots of the mucus sample to different concentrations of charged dextran;

- 5
- (c) measuring the viscoelasticity of each of the aliquots of the mucus sample after administration of the charged dextran, and
  - (d) determining the preferred dosage of charged dextran based on comparing the effect of the different concentrations of charged dextran on the viscoelasticity of the mucus sample.

005230 16541960

## ABSTRACT OF THE DISCLOSURE

The present invention is for a charged dextran, preferably dextran sulfate, as an improved mucoactive agent which can be used to improve viscoelasticity and clearance of respiratory tract mucus. The charged dextran can be used in the treatment of animals with impaired mucus clearance, mucus retention and/or mucus hypersecretion, such as cystic fibrosis, chronic bronchitis, bronchiectasis, bronchiolitis and bronchial asthma. Related methods of treatment and pharmaceutical compositions, particularly aerosolized dextran sulfate compositions are encompassed within the scope of the invention.

Figure 2

Effect of Dextran Sulfate on Tracheal Mucus Velocity (TMV)




Figure 3

Effect of Dextran Sulfate on Tracheal Mucus Rigidity Index




Figure 4

on Mucus % Solids





Figure 5



Treatment  
10  
11 NVCS

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)  
Approved for use through 9/30/00. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: ☒ Customer Number 1059 → ☐ Registered practitioner(s) name/registration number listed below

Place Customer  
Number Bar Code  
Label here

Name	Registration Number	Name	Registration Number
Daniel R. Bereskin	22,257	H. Samuel Frost	31,696
Richard J. Parr	22,836	Philip Mendes da Costa	33,106
H. Roger Hart	26,426	Robert B. Storey	33,108
David W.R. Langton	27,747	John R. Rudolph	38,003
C. Lloyd Sarginson	29,245	Robin L.A. Coster	38,016
Timothy J. Sinnott	31,083	Michael E. Charles	38,036

☒ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☒ Customer Number 1059 OR ☐ Correspondence address below

Name	Bereskin & Parr				
Address	Box 401				
Address	40 King Street West				
City	Toronto	State	Ontario	ZIP	M5H 3Y2
Country	Canada	Telephone	(416) 364-7311	Fax	(416) 361-1398

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])		Family Name or Surname	
Malcolm		King	
Inventor's Signature		Date	
Residence: City	Edmonton	State	Alberta
		Country	Canada
Post Office Address	3328-116 Street		
Post Office Address			
City	Edmonton	State	Alberta
		ZIP	T6J 3J2
		Country	Canada

☐ Additional inventors are being named on the supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto



